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The elimination of tuberculosis in Europe is a key public 
health priority,1 yet unprecedented levels of migration, 
especially from low-income or middle-income countries, 
pose challenges to achieving this goal. The overall 
incidence of tuberculosis in migrants is increasing 
in several countries, and—for example—migrants 
comprise more than 70% of all newly diagnosed cases 
in the UK, Sweden, the Netherlands, and Norway.2 
Migrants are at higher risk of clinical tuberculosis as a 
result of coming from countries with a high burden of 
infection, the poverty they might face on arrival, and a 
plethora of barriers to accessing free statutory health 
care and screening.3 Yet what constitutes a cost-eﬀ ective 
approach to migrant screening and understanding what 
to screen for, and who, where, and when to screen, 
remain contentious.
In The Lancet, Robert W Aldridge and colleagues4 
report the ﬁ ndings of a large retrospective cohort 
study of more than half a million migrants requesting 
a long-term entry visa to the UK (2005–12) who were 
screened for active tuberculosis in 15 high-incidence 
countries of origin before migration. Pre-entry 
screening data for this cohort are published elsewhere.5 
In the present study, the researchers explored what 
happens to migrants, free from active disease at the 
time of migration, after their arrival to the UK (mean 
follow-up 2·45 years per person). This research is 
timely, amid growing consensus that identiﬁ cation 
and treatment of latent tuberculosis before the disease 
becomes active could support elimination eﬀ orts,6,7 
representing a shift from the historical Europe-wide 
approach of screening for active disease on, or soon 
after, arrival. 
Aldridge and colleagues report that migrants 
screened before entry pose a negligible public health 
risk in terms of onward transmission (only 35 assumed 
index cases with an estimated crude rate of ﬁ ve per 
100 000 person-years [95% CI 4–8]) but are at risk 
of developing active tuberculosis after arrival to the 
UK, with 79·6% of cases notiﬁ ed after migration. The 
incidence of all forms of tuberculosis was lowest in the 
ﬁ rst year after arrival, and then peaked in the fourth 
year (222 per 100 000 person-years [95% CI 198–249]) 
before declining, with many cases resulting from 
reactivation of latent infection (301 cases with crude 
estimated incidence of 46 per 100 000 person-years 
[95% CI 42–52]). The data show, not unexpectedly, 
that some groups of migrants were over-represented 
among reactivation cases, including migrants from 
high-incidence countries (ie, countries with >350 cases 
per 100 000 people) and those with a chest radiograph 
compatible with tuberculosis but not bacteriologically 
conﬁ rmed when pre-screened in their countries of 
origin. Why the authors did not address the extent 
to which key risk factors such as socioeconomic 
deprivation in the host country and comorbidities (eg, 
HIV, diabetes mellitus) drive tuberculosis reactivation 
is unclear.
Although these data are limited to a particular 
subset of migrants requesting a long-term entry 
visa to the UK, they have potential implications 
for screening policies for the wider population of 
migrants across Europe, and suggest that screening 
and treatment for latent tuberculosis in migrants from 
high-incidence countries before departure, and within 
5 years of arrival in the host country, could strengthen 
control eﬀ orts. This approach is likely to be cost-
eﬀ ective.6,7
Aldridge and colleagues’ data support the notion 
that to eliminate tuberculosis in low-burden settings 
multiple initiatives will be needed. The UK is one of 
a few European countries now screening individuals 
before they migrate,8 and is pioneering a national 
strategy for latent tuberculosis testing in newly 
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On Sept 21, 2016, Mark Zuckerberg and his wife 
Priscilla Chan announced plans to invest US$3 billion 
in a mission to “cure, prevent or manage all diseases” 
by 2100, part of an earlier promise to donate 99% 
of their stock in Facebook, a company Zuckerberg 
founded. It is the latest example in a growing number 
of pledges by billionaires to give away their wealth for 
social causes rather than pass it down to descendants. 
On the face of it, the pledge by Zuckerberg and Chan is 
generous, worthy, and inspired. It encapsulates a new 
force in global health funding, philanthrocapitalism; a 
term coined to describe philanthropists harnessing the 
market to make their giving more eﬃ  cient and achieve 
better results. But is it good for health?
Aside from the unlikelihood of $3 billion being 
enough to manage all disease, there are at least three 
reasons why the global health community should 
pay more critical attention to the potentially adverse 
eﬀ ects of philanthrocapitalism.
The ﬁ rst is that philanthrocapitalist entities often 
lack suﬃ  cient accountability and disclosure of 
activities, especially when it comes to new ﬁ nancial 
vehicles established by a young generation of donors. 
Zuckerberg and Chan set up a limited liability company 
The black box warning on philanthrocapitalism
arrived migrants.9,10 We strongly support innovations in 
migrant screening and health-care delivery. However, 
policy makers need to be aware that thousands of 
migrants in the UK and Europe—including refugees, 
asylum seekers, and undocumented migrants from 
high-incidence countries—will completely bypass 
national screening programmes. Underlying all these 
new developments in the ﬁ eld of migrant health 
care, therefore, is the crucial need for innovative 
strategies to improve migrants’ access to host health 
systems, which will ensure timely screening for not 
only tuberculosis, but also other common infections 
that disproportionately aﬀ ect migrants, as well as 
delivery of vaccinations and aﬀ ordable health care and 
treatment. We, for example, are exploring one-stop 
testing for latent tuberculosis, hepatitis B and C virus 
infections, and HIV through emergency departments, 
where a high number of migrants are thought 
to present. 
Another essential consideration is that once screened, 
poor follow-up and low treatment completion rates 
are well documented in migrant patients—particularly 
for latent tuberculosis—which might render screening 
programmes ineﬀ ective and will necessitate unique 
approaches.2,11 Although the evidence base is incomplete, 
the European Centre for Disease Prevention and Control 
is currently developing much-awaited guidance on 
migrant screening.12 Aldridge and colleagues’ study 
therefore is a welcome contribution to evolving policy 
discussions around improving health outcomes in 
migrants across Europe. 
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